Cargando…

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

BACKGROUND: We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohashi, Yasuo, Shiba, Eiichi, Yamashita, Hiroko, Kurebayashi, Junichi, Noguchi, Shinzaburo, Iwase, Hirotaka, Yoshida, Michihiro, Fujimoto, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785605/ https://www.ncbi.nlm.nih.gov/pubmed/29063390 http://dx.doi.org/10.1007/s00520-017-3914-2

Ejemplares similares

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Kurebayashi, Junichi, et al.
Publicado: (2021)

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1990)

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
por: Kurebayashi, Junichi, et al.
Publicado: (2016)

A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin
por: Kim, Dohee, et al.
Publicado: (2019)

Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008)

A Case of Mental Retardation with Paraphilia Treated with Depot Leuprorelin
por: Park, Woo Sung, et al.
Publicado: (2014)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

Leuprorelin/tamoxifen: Impairment of ventricular repolarisation reserve: case report
Publicado: (2021)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment
por: Muratori, L., et al.
Publicado: (2019)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn, Ulf W, et al.
Publicado: (2013)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989)

Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study
por: Yang, Jianmei, et al.
Publicado: (2022)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Pelvic Ultrasound Parameters of Long-Acting Depot Formulation of Leuprorelin in the Treatment of Idiopathic Central Precocious Puberty in Girls
por: Yang, Kun, et al.
Publicado: (2021)

Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
por: Suzuki, Kazuhiro, et al.
Publicado: (2015)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs
por: Céspedes, María Virtudes, et al.
Publicado: (2016)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets
por: Klinge, Carolyn M.
Publicado: (2015)

Prenatal Exposure to Nonpersistent Endocrine Disruptors and Behavior in Boys at 3 and 5 Years
por: Philippat, Claire, et al.
Publicado: (2017)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Early endocrine disruptors exposure acts on 3T3-L1 differentiation and endocrine activity
por: Boudalia, Sofiane, et al.
Publicado: (2017)

The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot.
por: Matalliotakis, I M, et al.
Publicado: (2001)

Erratum: “Prenatal Exposure to Nonpersistent Endocrine Disruptors and Behavior in Boys at 3 and 5 Years”
por: Philippat, Claire, et al.
Publicado: (2018)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study
por: Xu, Lei, et al.
Publicado: (2019)

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Completion of 5-year adjuvant endocrine therapy in the community
por: Makubate, B, et al.
Publicado: (2010)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Tamoxifen down-regulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
por: Bergamaschi, Anna, et al.
Publicado: (2011)

The Impact of Endocrine Disruptors on Endocrine Targets
por: Gregoraszczuk, Ewa L., et al.
Publicado: (2013)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line
por: Won, Hye Sung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ui054o6q8p7ip6r5fdf818vq5i